According to Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) released its 2023 annual report. The group achieved operating income of 197 million yuan, a year-on-year decrease of 31.95%; achieved a net loss attributable to shareholders of listed companies of 151 million yuan, a year-on-year narrowing of 22.65%; realized a net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 182 million yuan, a year-on-year decrease of 10.9%; a basic loss per share.

The company is mainly engaged in R&D, production and sales of chemical prescription drugs. The company adheres to a market-based product development strategy. The product variety is rich, the structure is reasonable, the market position for many core products is outstanding, and it is in a leading position in the segmented product market. The company's leading products cover the three major fields of parenteral nutritional drugs, anti-infective drugs, and digestive medicines. While continuously consolidating the main varieties mentioned above, the company is actively expanding new high-margin varieties and has made great progress. Up to now, the company has obtained a total of 114 varieties and 221 drug production approval documents. Of these, 55 varieties have been included in the national medical insurance catalogue and 13 varieties have been included in the national basic drug catalogue.